PURPOSE: To evaluate the impact of cranial stereotactic radiotherapy (SRT) on overall survival (OS) of melanoma brain metastases (MBM) patients treated with combined nivolumab and ipilimumab (CNI) in a contemporary and real-world setting. METHODS/PATIENTS: The study was performed by using TriNetX, a global health network dataset of electronic medical records from patients in 49 healthcare organizations. We queried for patients with specific terms between January 2016 and December 2020 and run a propensity score matching (PSM) analysis. OS was estimated by Kaplan-Meier and log-rank test was applied. RESULTS: After initial query and PSM, 114 patients were selected in each cohort. Median OS was 327 days in CNI and not reached in the CNI + SRT cohort, with OS probability of 54.4 and 40.9%, respectively (log-rank P = .0057). CNI + SRT was associated with significantly decreased mortality (HR, 0.57; 95% CI 0.377-0.853; proportionality P = .0034). CONCLUSIONS: This real-world analysis showed that CNI + SRT led to an improvement in OS compared to CNI.
PURPOSE: To evaluate the impact of cranial stereotactic radiotherapy (SRT) on overall survival (OS) of melanoma brain metastases (MBM) patients treated with combined nivolumab and ipilimumab (CNI) in a contemporary and real-world setting. METHODS/PATIENTS: The study was performed by using TriNetX, a global health network dataset of electronic medical records from patients in 49 healthcare organizations. We queried for patients with specific terms between January 2016 and December 2020 and run a propensity score matching (PSM) analysis. OS was estimated by Kaplan-Meier and log-rank test was applied. RESULTS: After initial query and PSM, 114 patients were selected in each cohort. Median OS was 327 days in CNI and not reached in the CNI + SRT cohort, with OS probability of 54.4 and 40.9%, respectively (log-rank P = .0057). CNI + SRT was associated with significantly decreased mortality (HR, 0.57; 95% CI 0.377-0.853; proportionality P = .0034). CONCLUSIONS: This real-world analysis showed that CNI + SRT led to an improvement in OS compared to CNI.
Authors: Angela M Hong; Gerald B Fogarty; Kari Dolven-Jacobsen; Bryan H Burmeister; Serigne N Lo; Lauren E Haydu; Janette L Vardy; Anna K Nowak; Haryana M Dhillon; Tasnia Ahmed; Brindha Shivalingam; Georgina V Long; Alexander M Menzies; George Hruby; Katharine J Drummond; Catherine Mandel; Mark R Middleton; Claudius H Reisse; Elizabeth J Paton; Victoria Steel; Narelle C Williams; Richard A Scolyer; Rachael L Morton; John F Thompson Journal: J Clin Oncol Date: 2019-09-25 Impact factor: 44.544
Authors: Hussein A Tawbi; Peter A Forsyth; Alain Algazi; Omid Hamid; F Stephen Hodi; Stergios J Moschos; Nikhil I Khushalani; Karl Lewis; Christopher D Lao; Michael A Postow; Michael B Atkins; Marc S Ernstoff; David A Reardon; Igor Puzanov; Ragini R Kudchadkar; Reena P Thomas; Ahmad Tarhini; Anna C Pavlick; Joel Jiang; Alexandre Avila; Sheena Demelo; Kim Margolin Journal: N Engl J Med Date: 2018-08-23 Impact factor: 91.245
Authors: Celeste Lebbé; Nicolas Meyer; Laurent Mortier; Ivan Marquez-Rodas; Caroline Robert; Piotr Rutkowski; Alexander M Menzies; Thomas Eigentler; Paolo A Ascierto; Michael Smylie; Dirk Schadendorf; Mazhar Ajaz; Inge Marie Svane; Rene Gonzalez; Linda Rollin; Jennifer Lord-Bessen; Abdel Saci; Elena Grigoryeva; Jacopo Pigozzo Journal: J Clin Oncol Date: 2019-02-27 Impact factor: 44.544
Authors: Teresa Amaral; Felix Kiecker; Sarah Schaefer; Henner Stege; Katharina Kaehler; Patrick Terheyden; Anja Gesierich; Ralf Gutzmer; Sebastian Haferkamp; Jochen Uttikal; Carola Berking; David Rafei-Shamsabadi; Lydia Reinhardt; Friedegund Meier; Ante Karoglan; Christian Posch; Thilo Gambichler; Claudia Pfoehler; Kai Thoms; Julia Tietze; Dirk Debus; Rudolf Herbst; Steffen Emmert; Carmen Loquai; Jessica C Hassel; Frank Meiss; Thomas Tueting; Vanessa Heinrich; Thomas Eigentler; Claus Garbe; Lisa Zimmer Journal: J Immunother Cancer Date: 2020-03 Impact factor: 13.751